Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 19 of the 36 sources its claims cite were checked for support.
Abstract
BACKGROUND: Diabetes mellitus is associated with an increased risk of cardiovascular events. Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear. METHODS: We randomly assigned adults who had diabetes but no evident cardiovascular disease to receive aspirin at a dose of 100 mg daily or matching placebo. The primary efficacy outcome was the first serious vascular event (i.e., myocardial infarction, stroke or transient ischemic attack, or death from any vascular cause, excluding any confirmed intracranial hemorrhage). The primary safety outcome was the first major bleeding event (i.e., intracranial hemorrhage, sight-threatening bleeding event in the eye, gastrointestinal bleeding, or other serious bleeding). Secondary outcomes included gastrointestinal tract cancer. RESULTS: A total of 15,480 participants underwent randomization. During a mean follow-up of 7.4 years, serious vascular events occurred in a significantly lower percentage of participants in the aspirin group than in the placebo group (658 participants [8.5%] vs. 743 [9.6%]; rate ratio, 0.88; 95% confidence interval [CI], 0.79 to 0.97; P=0.01). In contrast, major bleeding events occurred in 314 participants (4.1%) in the aspirin group, as compared with 245 (3.2%) in the placebo group (rate ratio, 1.29; 95% CI, 1.09 to 1.52; P=0.003), with most of the excess being gastrointestinal bleeding and other extracranial bleeding. There was no significant difference between the aspirin group and the placebo group in the incidence of gastrointestinal tract cancer (157 participants [2.0%] and 158 [2.0%], respectively) or all cancers (897 [11.6%] and 887 [11.5%]); long-term follow-up for these outcomes is planned. CONCLUSIONS: Aspirin use prevented serious vascular events in persons who had diabetes and no evident cardiovascular disease at trial entry, but it also caused major bleeding events. The absolute benefits were largely counterbalanced by the bleeding hazard. (Funded by the British Heart Foundation and others; ASCEND Current Controlled Trials number, ISRCTN60635500 ; ClinicalTrials.gov number, NCT00135226 .).
Overview
CoChat Summary
TL;DR
In adults with diabetes and no evident cardiovascular disease, low-dose aspirin reduced serious vascular events but increased major bleeding, with absolute benefits largely counterbalanced by bleeding hazards. Aspirin did not reduce gastrointestinal or overall cancer incidence over a mean follow-up of 7.4 years.
Key findings
- Serious vascular events occurred in 658 aspirin-group participants (8.5%) vs. 743 placebo-group participants (9.6%) (rate ratio, 0.88; 95% CI, 0.79 to 0.97; P=0.01).
- Major bleeding occurred in 314 aspirin-group participants (4.1%) vs. 245 placebo-group participants (3.2%) (rate ratio, 1.29; 95% CI, 1.09 to 1.52; P=0.003), mostly gastrointestinal and other extracranial bleeding.
- No significant between-group difference was found for gastrointestinal tract cancer (157 [2.0%] vs. 158 [2.0%]) or any cancer (897 [11.6%] vs. 887 [11.5%]).
- Absolute effects: 91 patients would need to be treated to avoid a serious vascular event over 7.4 years, and 112 to cause a major bleeding event.
Methods
- Randomized trial of 15,480 adults with diabetes but no evident cardiovascular disease, assigned to aspirin 100 mg daily or matching placebo; factorial assignment also included n-3 fatty acids or placebo.
- Primary efficacy outcome was first serious vascular event (myocardial infarction, stroke or transient ischemic attack, or vascular death, excluding confirmed intracranial hemorrhage); primary safety outcome was first major bleeding event.
- Intention-to-treat time-to-event analyses used log-rank methods; mean follow-up was 7.4 years, with estimated mean adherence 70% in each group.
Limitations
- Stated: analyses for cancer had limited statistical power to detect hypothesized effects, and longer-term follow-up is planned or being continued.
- Stated: intention-to-treat analyses underestimate the effects of actual aspirin use because adherence was incomplete; secondary and exploratory outcomes were not adjusted for multiple comparisons, so confidence intervals should not be used to infer definitive subgroup or secondary effects.
- Evident from the text: participants were predominantly white (96.5%), had type 2 diabetes (94.1%), were recruited in the United Kingdom, and were well treated with cardioprotective therapies (e.g., 75.6% statin use in the aspirin group), which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 1 Not valid · 4 Not checked · 53 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear.”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
The Results report fewer serious vascular events with aspirin in both primary and secondary prevention trials. The Abstract’s Interpretation explicitly describes a reduction in occlusive events, while noting that bleeding risk must be weighed against this benefit in primary prevention. (LLM, conf=0.94)
- Supportedcites [2] 2. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-73. source
The Antiplatelet agents/anticoagulants recommendations (page not provided) recommend aspirin for patients with coronary artery disease and state that it reduces saphenous vein graft closure after bypass surgery. This supports the attributed claim that aspirin reduces occlusive vascular events in the guideline’s secondary-prevention setting; the separate statement about first events in diabetes is not part of the quoted claim. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“On average, however, the approximate 50% higher risk of bleeding with aspirin use than with control counterbalanced much of the benefit in these low-risk patients.”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
The Results report about a 50% increase in major gastrointestinal and other extracranial bleeding with aspirin in primary-prevention trials (RR 1.54). The Discussion says aspirin’s absolute benefits are much smaller in primary than in secondary prevention and that its benefits and bleeding hazards can be approximately balanced, supporting the claim about low-risk patients. (LLM, conf=0.93)
plainstates a causen = 95,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Only approximately 4% of participants in those trials had diabetes, and the lower relative risk among them was similar to that observed among participants without diabetes (as was also observed in the context of secondary prevention).”
What the sources say
- Partly supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that, in the primary-prevention trials, the proportional reduction in serious vascular events did not differ significantly by history of diabetes. This supports the main comparison, but the passages do not establish the citing sentence’s approximately 4% figure or its diabetes-specific comparison in secondary prevention. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The 2009 Antithrombotic Trialists' Collaboration meta-analysis involving 95,000 patients in six primary prevention trials showed that assignment to aspirin use led to a 12% (95% confidence interval [CI], 6 to 18) lower risk of serious vascular events than control. 1”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a causen = 95,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear.”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
The Results report that aspirin increased major gastrointestinal and other extracranial bleeds in primary prevention trials, with a significant excess of major bleeds also observed in secondary prevention trials. This supports the attributed claim that aspirin increases bleeding risk. (LLM, conf=0.94)
- Partly supportedcites [2] 2. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-73. sourceExperimental — accuracy not yet measured
The Antiplatelet agents/anticoagulants recommendations (page unavailable) state that warfarin used with aspirin and/or clopidogrel is associated with increased bleeding risk. The References also list a study of bleeding complications at different aspirin doses, but the guideline passage does not establish the unqualified claim that aspirin use alone increases bleeding risk. (LLM, conf=0.81)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 72 claims and every source verdict.
- It may state two separate claims as one. 16
- Probably not a substantial claim. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The benefit of ASA in the ASCEND trial was observed on top of statins (75% of patients) and/or anti-hypertensive (∼60% of patients) drugs.292”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [292]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For people > 70 years of age (with or without diabetes), the balance appears to have greater risk than bene fi t (144,146).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [144]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“however, the ASCEND trial found benefit of low-dose aspirin in those in this weight range, which would not validate this suggested hypothesis (179).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [179]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For people >70 years of age (with or without diabetes), the balance appears to have greater risk than benefit (179,181).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [179]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There were no significant differences by sex, weight, or duration of diabetes or other baseline factors, including ASCVD risk score.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [179]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Rivaroxaban with or without aspirin in stable cardiovascular disease
Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709118 · Cited by 2,438
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318235eb4d · Cited by 1,759
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497
Rothwell, P. M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61543-7 · Cited by 1,351
Rothwell, P. M., Wilson, M., Price, J. F., Belch, J. F., Meade, T. W., & Mehta, Z. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60209-8 · Cited by 984
Cited by
Items 701–800 of 1,171
Aspirin and Primary Prevention of Colorectal Cancer: A Still-Evolving Story
McNeil, J. J. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab010 · Cited by 4
Dehmer, S. P., O’Keefe, L. R., Evans, C. V., Guirguis‐Blake, J., Perdue, L. A., & Maciosek, M. V. (2022) · JAMA · doi:10.1001/jama.2022.3385 · Cited by 53
Ruiz‐García, A., Pallarés‐Carratalá, V., Serrano-Cumplido, A., Escobar-Cervantes, C., Barquilla-García, A., Divisón, J. A., Turégano-Yedro, M., Prieto-Díaz, M. Á., Cinza‐Sanjurjo, S., Alonso-Moreno, F. J., et al. (2022) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2021.12.002 · Cited by 2
Kim, D. G., Kim, S. H., Lee, J. Y., et al. (2024) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2024.04.002 · Cited by 2
Alkhalaf, A., AlJabr, Q., Mulla, K. A., Almubarak, D., Khan, A. S., AL-Jaziri, Z. Y., & Al-Bahrani, I. R. (2025) · Medicina · doi:10.3390/medicina61010132 · Cited by 3
Valeriani, E., Sesso, H. D., Pastori, D., Menichelli, D., Pignatelli, P., & Violi, F. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2580-6931 · Cited by 2
Long-term aspirin use and heart failure incidence: A patient-level pooled analysis study
Xiao, M., Xing, Z., Schocken, D. D., Zgibor, J. C., & Alman, A. C. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.08.025 · Cited by 2
Association of cardiometabolic risk burden with gastrointestinal bleeding in aspirin users
Wei, Y., Yan, J., Gao, Z., Wei, H., Qiu, Z., Xiao, J., & Huang, W. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04347-3 · Cited by 3
Fawsitt, C. G., Thom, H. H. Z., Aceituno, D., Jarde, A., Larsen, S., Lübker, C., Kayongo, E., Keeney, E., & FOOS, V. (2025) · PharmacoEconomics · doi:10.1007/s40273-025-01555-3 · Cited by 2
Cussen, A., & Littler, K. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-106823 · Cited by 8
Rørth, R., Gerds, T. A., Kosjerina, V., Carstensen, B., Persson, F., & Rossing, P. R. (2025) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2025.100286 · Cited by 2
Low-Dose Aspirin for Cardiovascular Disease Primary Prevention in Patients With Giant Cell Arteritis
Beydon, M., Hajage, D., Guédon, A. F., Carrat, F., Séror, R., & Tubach, F. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.6579 · Cited by 4
Yu, C., Hussain, S. M., Fransquet, P., Tran, C., Tonkin, A. M., Nelson, M. R., Reid, C. M., Neumann, J. T., Williamson, J. D., Eaton, C. B., et al. (2026) · Stroke · doi:10.1161/strokeaha.125.054979 · Cited by 2
Burn, J., Borthwick, G. M., Elliott, F., Macrae, F., Ong, K. R., Kraus, A. C., Arber, N., Mecklin, J., Alonso, Á., Woodward, E. R., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00114-7 · Cited by 8
Papel de la Aspirina® como tratamiento antiagregante en prevención primaria. Puesta al día
Jiménez-García, N., Lima, J. D. L. T., & Alegría, J. G. (2019) · Medicina Clínica · doi:10.1016/j.medcli.2019.05.024 · Cited by 3
Rodríguez‐Martín, S., García‐Lledó, A., Gil, M., Barreira‐Hernández, D., Rodríguez, A., & de Abajo, F. J. (2020) · Medicina Clínica · doi:10.1016/j.medcli.2019.10.012 · Cited by 2
Oh, T. K., & Song, I. (2020) · Yonsei Medical Journal · doi:10.3349/ymj.2020.61.12.997 · Cited by 3
Armario, P., Brotons, C., Elosúa, R., de Leciñana, M. A., Castro, A., Clarà, A. B. I., Cortés, O., Rodríguez, Á. D., Herranz, M., Justo, S., et al. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.11.004 · Cited by 7
The role of platelets in the pathogenesis of atherosclerosis
Nikolaeva, T. O. (2021) · Ateroscleroz · doi:10.52727/2078-256x-2021-3-106-119 · Cited by 3
Thanabalasingham, G., Lumb, A. N., Murphy, H. R., Scanlon, P. H., Buckingham, J., Tesfaye, S. H., Pokrajac, A., Choudhary, P., Divilly, P., Dhatariya, K., et al. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198851899.003.0015 · Cited by 2
Fall, M., Le, H.-H., Bouvier, A., Louis, C., Elias, E., Yacoub, K., Al‐Gobari, M., Grenet, G., Seye, M., Simeon, G., et al. (2022) · Therapies · doi:10.1016/j.therap.2022.04.004 · Cited by 3
Acetylsalicylic acid in primary prevention of cardiovascular disease
Miklík, R., & Jiravský, O. (2022) · Vnitřní lékařství · doi:10.36290/vnl.2022.050 · Cited by 2
Wang, X., Chen, X., Liu, W., Liang, W., & Liu, M. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s391259 · Cited by 2
Liao, Y.-H., Hsu, R., Wang, T.-H., Wu, C., Huang, S.-Y., Hsu, C. Y., Hsu, W., & Liu, D. (2022) · Cancers · doi:10.3390/cancers15010097 · Cited by 2
Adherence to European guidelines for the use of aspirin in primary health care
Moita, C. F., Marau, G., Corte-Real, S., & Dantas, A. (2023) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2022.03.007 · Cited by 2
What Is the Role of Aspirin in Primary Prevention in Patients With Elevated Lp(a)?
Tsimikas, S. (2023) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2023.3.e7 · Cited by 2
Clinical Management of Patients With Stable Ischemic Heart Disease
Dey, S., Wang, A. Y.-D., McMaster, M., Sanghavi, N., Frishman, W. H., & Aronow, W. S. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000557 · Cited by 2
Zhu, J., Shi, Y., Cui, Y., & Yan, W. (2024) · Health Policy and Technology · doi:10.1016/j.hlpt.2024.100842 · Cited by 2
Needs-based considerations for the role of low-dose aspirin along the CV risk continuum
Santilli, F., Albrecht, G., Blaha, M. J., Lanas, Á., Li, L., & Sibbing, D. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100675 · Cited by 3
Wang, Z., Liu, X., Zhang, S., Hu, X., Tian, Y., & Li, Q. (2024) · International Journal of Stroke · doi:10.1177/17474930241288367 · Cited by 3
Thyagaturu, H. S., Ali, S., Seetharam, K., Upreti, P., Doddi, A., Atti, L., Roma, N., Lacoste, J. L., Angirekula, A., Salami, J., et al. (2024) · Cardiology and Therapy · doi:10.1007/s40119-024-00385-2 · Cited by 2
Hong, D., Lee, S. H., Heo, J., Shin, D., Cho, J., Güallar, E., Joh, H. S., Kim, H. K., Ha, J., Choi, K. H., et al. (2024) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2024.11.001 · Cited by 2
Gao, C., Hou, Q., Cao, H., Li, C., Peng, X., Han, Q., Wu, S.-L., & Li, K. (2025) · Journal of International Medical Research · doi:10.1177/03000605251315359 · Cited by 2
Sammons, E. L., Bowman, L. J., Stevens, W., Buck, G. A. N., Hammami, I., Parish, S., & Armitage, J. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-090605 · Cited by 2
The aspirin heart disease prevention conundrum
Superko, H. R., Sninsky, J. J., & Garrett, B. C. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101013 · Cited by 2
Aspirin reduces the risk of type 2 diabetes associated with COVID-19
Trimarco, V., Izzo, R., Pacella, D., Manzi, M. V., Jankauskas, S. S., Gallo, P., Rozza, F., Giugliano, G., Spinelli, A. M., Esposito, G., et al. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00072-3 · Cited by 3
Lin, Y., Chen, C., Huang, L.-Y., Chen, B., Shao, Y. J., & Huang, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-10215-7 · Cited by 3
Rawal, A., Cave, B. E., Ardeshna, D. R., Hana, D., Ibebuogu, U. N., & Khouzam, R. N. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.07.05 · Cited by 2
A year in type 2 diabetes mellitus: 2018 review based on the Endorama lecture
Paschou, S. Α., & Alexandrides, T. K. (2019) · HORMONES · doi:10.1007/s42000-019-00139-z · Cited by 4
Les méta-analyses en recherche clinique : forces et faiblesses
Monnier, L., Colette, C., Schlienger, J.-L., & Halimi, S. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2019.12.011 · Cited by 5
Primary prevention of cardiovascular diseases in diabetes mellitus: 2020 strategy
Novikov, V. I., & Novikov, K. Y. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-4-42-49 · Cited by 2
Cuba, M. A. M., Martínez, J. E., & Galeano, I. O. (2020) · Anales de la Facultad de Ciencias Médicas (Asunción) · doi:10.18004/anales/2020.053.02.53 · Cited by 3
Balletshofer, B. M., Böckler, D., Diener, H., Heckenkamp, J., Ito, W. D., Katoh, M., Lawall, H., Malyar, N. M., Oberländer, Y., Reimer, P., et al. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1194-1745 · Cited by 2
Study on food nutrition and association with Diabetes Mellitus
Wan, S. (2020) · IOP Conference Series Earth and Environmental Science · doi:10.1088/1755-1315/615/1/012109 · Cited by 5
Major, R., & Burton, J. O. (2021) · Kidney International · doi:10.1016/j.kint.2020.09.008 · Cited by 2
Capodanno, D. (2018) · EuroIntervention · doi:10.4244/eijv14i11a207 · Cited by 2
Aspirin in people with diabetes: Time to clean up the prescription list?
Vouillarmet, J., & Aboyans, V. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.02.005 · Cited by 3
Precision medicine for diabetes management and primary cardiovascular prevention
Leggio, M., Tiberti, C., Armeni, M., Limongelli, G., & Mazza, A. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12899 · Cited by 2
Thrombozytenaggregationshemmer (Update 2019)
Leitlinien, D. A., Wascher, T. C., & Saely, C. H. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-018-1437-6 · Cited by 2
The Influence of Unsaturated Fatty Acids for Atherosclerosis in Recent Years
Bando, M., & Bando, H. (2019) · Journal of Obesity and Diabetes · doi:10.33805/2638-812x.110 · Cited by 2
Aspirin Has a Neutral Effect in Preventing Future Cardiovascular Events in Vasospastic Angina
Lee, K. Y., Shin, D. I., Her, S., Han, S. H., Ahn, Y., Kim, D., Choi, D., Kwon, H. M., Gwon, H., Rha, S., et al. (2019) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2019.1.e4 · Cited by 2
The role of aspirin as antiaggregant therapy in primary prevention. An update
Jiménez-García, N., Lima, J. D. L. T., & Alegría, J. G. (2019) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2019.05.005 · Cited by 4
Панченко, Е. П. (2021) · Aterotromboz = Atherothrombosis · doi:10.21518/2307-1109-2021-11-1-89-105 · Cited by 2
Dietary Fat: The Good, the Bad, and What Is Best?
Sapp, P. A., Petersen, K. H., & Kris‐Etherton, P. M. (2022) · Nutrition and health · doi:10.1007/978-3-030-82515-7_29 · Cited by 3
Ducrocq, G., Bhatt, D. L., Lee, J., Kui, N., Fox, K. M., Harrington, R. A., Leiter, L. A., Mehta, S. R., Kiss, R. G., James, S. K., et al. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.03.008 · Cited by 2
Sueda, Y., Okazaki, R., Funaki, Y., Hasegawa, Y., Ishikawa, H., Hirayama, Y., Inui, G., Harada, T., Takata, M., Morita, M., et al. (2022) · Yonago acta medica · doi:10.33160/yam.2022.05.001 · Cited by 2
Cardiodiabetology: newer pharmacologic strategies for reducing cardiovascular disease risks
Wong, N. D. (2022) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2022-0065 · Cited by 2
THE ABCDE'S OF PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE.
Blumenthal, R. S., & Alfaddagh, A. (2022) · PubMed Central · Cited by 3
Abtan, J., Bhatt, D. L., Elbez, Y., Ducrocq, G., Goto, S., Smith, S. C., Ohman, E. M., Eagle, K. A., Fox, K. M., Harrington, R. A., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.10.132 · Cited by 2
Sun, Y., Xu, Y., Wang, N., Wang, F., Hui, C., Cheng, Y., Cui, M.-J., Huang, Q.-Y., Xu, J., & Kong, X.-M. (2022) · Talanta · doi:10.1016/j.talanta.2022.124116 · Cited by 2
Han, H. J., Kim, J., Park, K. Y., Park, S. K., Chung, J., & Kim, Y. B. (2023) · Acta Neurochirurgica · doi:10.1007/s00701-023-05555-0 · Cited by 4
Low-dose aspirin therapy for primary prevention of cardiovascular disease: where are we at?
Pugliese, N. R., & Taddei, S. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad110 · Cited by 3
Balletshofer, B. M., Böckler, D., Diener, H., Heckenkamp, J., Ito, W. D., Katoh, M., Lawall, H., Malyar, N. M., Qiu, H. J., Reimer, P., et al. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01043-2 · Cited by 4
Limpijankit, T., Jongjirasiri, S., Meemook, K., Unwanatham, N., Rattanasiri, S., Thakkinstian, A., & Laothamatas, J. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02313-1 · Cited by 3
Vernstrøm, L., Laugesen, E., Grove, E. L., Baier, J. M., Gullaksen, S., Hvas, A., Poulsen, P. L., & Funck, K. L. (2019) · Diabetic Medicine · doi:10.1111/dme.13978 · Cited by 3
Should all diabetic patients be on aspirin for primary prevention?
Khalil, S., Darmoch, F., Shah, Z., & Alraies, M. C. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1642107 · Cited by 3
Aspirin for primary prevention of cardiovascular disease in women
SHUFELT, C. L., & Manson, J. E. (2020) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001547 · Cited by 3
Rubenfire, M., Weinberg, R. L., Jamé, S., Oral, E. A., Jamerson, K., & Brook, R. D. (2020) · Journal of Clinical Cardiology and Cardiovascular Therapy · doi:10.31546/2633-7916.1008 · Cited by 2
Primary Prevention of Coronary Artery Disease
Bhattacharya, R., & Natarajan, P. (2020) · Springer eBooks · doi:10.1007/978-3-030-45792-1_5 · Cited by 2
A one-size-fits-all polypill strategy for primary prevention in the era of precision medicine?
Liuzzo, G., & Patrono, C. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1064 · Cited by 2
Enhoş, A., & Karaçöp, E. (2021) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s307768 · Cited by 2
Initial Diagnosis and Management of Type 2 Diabetes Mellitus
Suda, N., & Lee, H. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-84367-0_39 · Cited by 3
Review of Target-Specific Anticoagulation Reversal Agents
Smetana, K. S., Counts, J., Sodhi, A., & May, C. C. (2022) · Critical Care Nursing Quarterly · doi:10.1097/cnq.0000000000000400 · Cited by 2
Brett, A. S. (2022) · JAMA · doi:10.1001/jama.2022.2460 · Cited by 3
What Is So Hard About Aspirin for Primary Prevention?
Pignone, M. P. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.502 · Cited by 2
A Systematic Review of Methods used to Conduct Decentralised Clinical Trials
Rogers, A. (2022) · doi:10.26226/m.619bb9febe545488cfae505f · Cited by 2
McFadyen, J. D., & Gardiner, E. E. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318337 · Cited by 2
Cerebrovascular Disease and Diabetes
Amory, C. F., Weinberger, J. M., & Smith, T. S. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch51 · Cited by 2
Hof, J. V., Duval, S., Oldenburg, N. C., Misialek, J. R., Eder, M., Jones, C., Finnegan, J. R., & Luepker, R. V. (2021) · Preventive Medicine · doi:10.1016/j.ypmed.2021.106589 · Cited by 1
Stellenwert der ASS-Therapie in der kardio- und zerebrovaskulären Prävention
Gassanov, N., Eicke, B. M., & Er, F. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1578-6802 · Cited by 1
Maleki, M., & Hosseini, Z. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-80915-3.00012-0 · Cited by 1
Kordowski, T., Tatara, T., & Fronczak, A. (2019) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.29 · Cited by 1
Hemostatic abnormalities associated with diabetes and their clinical implications
Kietsiriroje, N., Ajjan, R., & Grant, P. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00005-x · Cited by 2
Scarfo, N. L., Thomas, V., Mayboroda, M. S., & Hewage, U. (2023) · Internal Medicine Journal · doi:10.1111/imj.16079 · Cited by 2
Wongcharoen, W., Osataphan, N., Prasertwitayakij, N., Suwannasom, P., Suraamornkul, S., Wongtheptian, W., Gunaparn, S., Sirikul, W., & Phrommintikul, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-41864-1 · Cited by 2
Hatami, N., Malekpour, M., Farzadfar, F., Seyedifar, M., & Soleymani, F. (2023) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-023-00481-z · Cited by 1
Shubietah, A. R. M., Marin, M. P., Rajab, I. M., Oweidat, M. H., Zayed, A., & Hmeedan, A. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000722 · Cited by 2
Geriatric Pharmacotherapy Case Series: Clotting and Gender-Affirming Care
Mertz, A., Fair, C., & Pol, J. (2024) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2024.319 · Cited by 1
Premature coronary artery disease primary prevention – Searching for the Holy Grail
Alcaravela, J. (2024) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2024.11.002 · Cited by 1
Type 2 Diabetes Mellitus and Stroke: Understanding the Connection
Abdullah, F. (2024) · Nutritional neurosciences · doi:10.1007/978-981-97-6818-9_7 · Cited by 2
Pharmacists’ Intervention in Inappropriate Aspirin Prescribing in a Geriatric Primary Care Clinic
Tulcewicz, P., Atkinson, K., Koff, A., & Smith, C. (2025) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2025.145 · Cited by 1
Aspirin for primary prevention: time to reconcile discrepancies
Mazzola, M., & Caterina, R. D. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf365 · Cited by 3
Antiplatelet Therapy in Coronary Artery Disease
Laudani, C., Capodanno, D., & Angiolillo, D. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-96360-5_9 · Cited by 1
Aspirin Use in Secondary Prevention of Myocardial Infarction: A Systematic Review and Meta-Analysis
Maimani, B. A., Akhter, R., Akhond, S. B., Saha, S., Das, D., Sraya, T. I., Islam, M. A., & Jihan, M. R. F. (2025) · Cureus · doi:10.7759/cureus.95092 · Cited by 2
Théberge, E. T., Selvage, C., Thomas, A., LeMoine, K. M., Robichaud, R., Zhou, L. W., Yeung, D. F., West, M. L., the CFDI investigators group, Sirrs, S., et al. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-04098-0 · Cited by 2
Haber, M., Nasr, M. S., Etri, H. A., & Nasr, S. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1664802 · Cited by 2
Zhao, Z., Li, Q. X., Bai, X., Zhai, E., Dai, W., Yan, Q., Zhang, T., Huang, Z., Huang, Z., Meng, F., et al. (2025) · Advanced Science · doi:10.1002/advs.202517747 · Cited by 1
Phakwiwat, K., Matesareyapong, K., Limpaarayakul, T., & Lawongsa, K. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01823-1 · Cited by 2
Estándares SEA 2026 para el control global del riesgo vascular
Mostaza, J. M., Pintó, X., Armario, P., Guijarro, C., Masana, L., Real, J. T., Arrobas-Velilla, T., Baeza‐Trinidad, R., Calmarza, P., Cebollada, J., et al. (2026) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2025.500889 · Cited by 2
Lobkovich, A. M., Ferrari, H. M., Martirosov, A. L., Mohammad, I., Berlie, H. D., Garwood, C. L., & Lipari, M. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70121 · Cited by 1
Metadata
- Authors
- The ASCEND Study Collaborative Group
- Affiliations
- MRC Population Health Research Unit (GB)
- Corresponding author
- The ASCEND Study Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-10-18
- Volume
- 379
- Issue
- 16
- Pages
- 1529-1539
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899755710
- Cited by
- 1,200
- References
- 23
- Citations by year
- 2026: 66 · 2025: 105 · 2024: 123 · 2023: 117 · 2022: 170 · 2021: 176 · 2020: 193 · 2019: 214 · 2018: 33
- FWCI
- 116.42
- Type
- journal article
- Language
- en
- Open access
- green
- ora.ox.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Oxford University Research Archive (ORA) (University of Oxford) (submittedVersion)
- Funders
- Mylan EPD
- Solvay Pharmaceuticals
- Bayer Schering
- British Heart Foundation (SP/03/02, SP/08/010/25939, SP/14/13/31114)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- diabetes mellitus, aspirin, primary prevention, cardiovascular events, major bleeding, gastrointestinal bleeding, intracranial hemorrhage, myocardial infarction, stroke, cancer incidence, benefits and risks, ASCEND trial, occlusive vascular disease, antiplatelet therapy, cardiovascular risk reduction, gastrointestinal cancer, cancer mortality
- MeSH terms
- Aged, Aged, 80 and over, Aspirin, Cardiovascular Diseases, Diabetes Mellitus, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Primary Prevention, Risk Factors, Poisson Distribution, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.